

PMcardio for Organizations

An AI-powered ECG interpretation platform enabling accurate diagnosis at first point of contact, ensuring rapid patient referral to specialized care.

Leading the AI Revolution in Cardiovascular Care

Powerful Medical Leadership Team

Powerful Medical leads one of the most significant shifts in modern medicine: augmenting human-made clinical decisions with artificial intelligence. On a mission to improve the outcomes and reduce preventable deaths among cardiovascular patients, we developed PMcardio, an AI-powered diagnostic solution. Backed by 28 world-class cardiologists, our expert team of over 60 people includes esteemed physicians, data scientists, software engineers, and business leaders, based in the USA, Belgium, and Slovakia.



Martin Herman
Chief Executive Officer
Co-Founder



Robert Herman, MD
Chief Medical Officer
Co-Founder



**Prof. Jozef
Bartunek, MD, PhD**
VP Medical Strategy



Simon Rovder
Chief Technology Officer
Co-Founder



**Prof. Robert
Hatala, MD, PhD**
Chief Scientist
Co-Founder



Sarah Weiss
Head of Marketing



Martin Popovic
Head of Regulatory
& Compliance



Viktor Jurasek
Chief Product Officer
Co-Founder



**Gabriela
Sklencarova**
Head of Infrastructure



Felix Bauer
Chief Operating Officer
Co-Founder

Physician Advisory Board



**Prof. Stephen W.
Smith, MD**

Emergency Medicine

Professor of Emergency Medicine,
Founder of Dr. Smith's ECG blog



**Prof. Emanuele
Barbato, MD, PhD**

Interventional Cardiology

Head of Cardiology at Sain't Andrea
Hospital in Rome and President of EAPCI -
European Society of Cardiology



**Ass. Prof.
Leor Perl, MD**

Interventional Cardiology

Director of Complex Cardiac Interventions
Service and Chief Innovation Officer, Rabin
Medical Center at Clalit Health



**Ass. Prof. Pendell
H. Meyers, MD**

Emergency Medicine

Professor of Emergency Medicine,
Founder of Dr. Smith's ECG blog



330k+

patients screened through
the AI ECG platform
since launch

35k+

healthcare
professionals using
our technology

10+

medical publications
in peer-reviewed
journals

30+

international clinical
research network of
leading institutions

50+

interdisciplinary team of
physicians, AI researchers, software
engineers and regulatory specialists

Time is survival

Patients presenting with acute coronary occlusion need emergent angiography in under 90 minutes to prevent irreversible damage.



"A 12 lead ECG is the most important diagnostic tool to identify patients with an acutely occluded coronary artery. Every day, nearly 100 patients undergo urgent 12-lead ECG testing during triage in our center."



Scott Sharkey, MD
Chief Medical Officer
Minneapolis Heart Institute

- Chest pain is the most common symptom in patients presenting to emergency departments.
- A 12-lead ECG is performed to quickly rule-in patients with an acutely occluded coronary artery.
- These patients need to be referred to a primary PCI center within 90 minutes from first medical contact to prevent irreversible heart damage.

The rule-in pathway for early identification of STEMI patients is suboptimal, causing frequent misidentification, wasted resources and physician burnout.





A secure care coordination platform ensuring accurate diagnostics and fast referral to specialized care.



PMcardio is an ECG interpretation platform enabling healthcare professionals to diagnose 39 cardiac abnormalities at the first point of contact. Its OMI AI model is trained to detect acute coronary occlusion without relying on ST-elevation, ensuring streamlined triage and enhanced clinical care coordination by healthcare providers.

The platform is compatible with all standard ECG devices and works in any clinical setting, either as a stand-alone mobile and web application or an end-to-end integrated solution.



Pending 510(k)
Clearance*



HIPAA
Compliant



EU MDR Medical
Device Class II(b)



QMS
ISO 13485



ISO 27001
Compliant



SOC 2
Compliant



GDPR
Compliant



Industry-leading
Cloud Security

*PMcardio is CE-marked as class IIb medical device under EU MDR and only certified for marketing in the European Union and the United Kingdom. PMcardio technology has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region. Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Enterprise Level Features Enabling Secure Patient Management



Certified AI ECG modules

Accurately diagnose occlusion myocardial infarction (OMI) in patients presenting with chest pain.



Enterprise security

Keep your data safe with the highest security, compliance, and privacy standards.



Central report management

Access all ECGs in your organization through a single admin dashboard.



PACS / CVIS integration

Seamlessly incorporate advanced AI models into your existing hospital systems and workflows.



User administration

Efficiently administer team members with user permissions that ensure the right level of access and functionality for everyone.



Early access to advanced AI diagnostics

Get early access to experimental features like OMI explainability and new AI models in development.

PMcardio in Integrated Health Systems

PMcardio seamlessly integrates into clinical workflows across the healthcare system at all tier levels. Utilizing the platform via mobile, web or HIS/EHR integrations, healthcare professionals are enabled to efficiently process ECGs for patients at every stage of care, from initial triage to those admitted to cardiac departments, ensuring rapid and accurate diagnostics.




Activate Cath Lab!

Notification + confirmation by a cardiologist

Occlusion myocardial infarction

ACUTE High confidence

! Immediately refer the patient to a PCI-capable centre



Bypass emergency department


International Clinical Validations & Research

European Heart Journal
Digital Health


PMcardio OMI AI ECG model significantly outperforms current standard of care in detecting acute coronary occlusion using 12-lead ECGs.

 **3 sites**
2 US & 1 EU

 **18,616 ECGs**
in AI development

 **2,222 patients**
in validation cohort


 HennepinHealthcare  Stony Brook Medicine  Cardiovascular Center
OLV Aalst



Robust performance to detect acute coronary occlusion using only 12-lead ECG blinded to other clinical information.

Sensitivity

(at matched Specificity)



2x higher sensitivity compared to the standard of care.

External Independent Evidence

To facilitate the integration of the PMcardio OMI AI Model into clinical practice, ongoing validation is being conducted in cooperation with 32 clinical partners across 25 countries. The research initiative encompasses the analysis of over 84 000 consecutive patients presenting with chest pain, underscoring our commitment to understanding the model's applicability and accuracy in diverse clinical scenarios.

 Cardiovascular Center
OLV Aalst

34%

reduction in STEMI activation time

 Stony Brook University

10.3h

faster identification of STEMI equivalents

 SSMHealth.

2x

higher sensitivity compared to cardiologists

 HennepinHealthcare

58%

reduction in FP STEMI activations

 HennepinHealthcare

100%

true positive STEMI detected

 UNIKLINIK
KÖLN

99.8%

specificity in all-comer chest pain



"I think that pre-hospital diagnosis of OMI is a huge area of opportunity for the Queen of Hearts. We can save more hearts with early pre-hospital recognition and cath lab activation and reduce the over/under triage of cath lab resources."



Michael Perlmutter, MD
Flight paramedic at Hennepin County Medical Center's Emergency Medicine Department

"This AI innovation symbolizes the merger of technology with cardiac care and paves the way for fast and accurate diagnosis in a variety of clinical scenarios. The superior accuracy of the AI model in detecting acute heart attacks, compared to traditional methods, underlines the potential of this model to revolutionize the way heart attacks are detected and treated."



Dr. Dan Schefault
Co-Director and Head of Coronary Care Unit at the Cardiovascular Center Aalst

"Activating the cath lab for a patient presenting with symptoms of ACS isn't always as straightforward as recognizing a STEMI on the ECG. Because there are many more criteria to consider when evaluating ECGs for OMIs compared to STEMIs, it can be helpful to have an extra pair of well-trained eyes double checking your work - and that's exactly what PMcardio's OMI AI Model provides."



Mark Hellerman, MD
Cardiology Fellow, Stony Brook University Hospital

As seen on

The
Guardian

thebmj

Forbes



Cardiovascular
CME Podcasts



powerfulmedical.com

omi@powerfulmedical.com